Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3109/13506129.2015.1063485 http://scihub22266oqcxt.onion/10.3109/13506129.2015.1063485 C4549186!4549186!26193961     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Amyloid 2015 ; 22 (3): 175-80 Nephropedia Template TP {{tp|p=26193961|t=2015. Personalized Medicine Approach for Optimizing the Dose of Tafamidis to Potentially Ameliorate Wild-type Transthyretin Amyloidosis (Cardiomyopathy) |pdf=|usr=}}{{26193961}} gab.com Text Personalized Medicine Approach for Optimizing the Dose of Tafamidis to Potentially Ameliorate Wild-type Transthyretin Amyloidosis (Cardiomyopathy) JO: Amyloid http://www.kidney.de/pget.php?&tw=1&pmid=26193961 #FOAvip Placebo-controlled clinical trials are useful for identifying the dose of a drug candidate that produces a meaningful clinical response in a patient population. Currently Pfizer, Inc. is enrolling a 400-person clinical trial to test the efficacy of 20 or 80 mg of tafamidis to ameliorate transthyretin (TTR)-associated cardiomyopathy using clinical endpoints. Herein, we provide guidance for how to optimize the dose of tafamidis for each WT TTR cardiomyopathy patient using its mechanism of action as the key readout, i.e., we identify the dose of tafamidis that maximally kinetically stabilizes TTR in the blood. Tetramer dissociation is rate limiting for TTR aggregation, which appears to drive the pathology in the TTR amyloidosis. Hence we measure the TTR tetramer dissociation rate (kinetic stability) in the patients? plasma as a function of tafamidis dose to optimize the dose employed to maximize kinetic stability. Historical data tells us that a subset of patients exhibiting higher tafamidis plasma concentrations are maximally kinetically stabilized at the 20 mg tafamidis dose, whereas the patient studied herein required a 60 mg once daily dose to achieve maximum kinetic stabilization. We anticipate that establishing the dose of tafamidis that achieves maximal TTR kinetic stabilization will translate into a maximal clinical effect, but that remains to be demonstrated. Twit Text FOAVip Personalized Medicine Approach for Optimizing the Dose of Tafamidis to Potentially Ameliorate Wild-type Transthyretin Amyloidosis (Cardiomyopathy) ????Amyloid http://www.kidney.de/pget.php?&tw=1&pmid=26193961 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26193961 #FOAvip English Wikipedia <ref>{{Cite pmid|26193961}}</ref> Personalized Medicine Approach for Optimizing the Dose of Tafamidis to Potentially Ameliorate Wild-type Transthyretin Amyloidosis (Cardiomyopathy) #MMPMID26193961 Cho Y; Baranczak A; Helmke S; Teruya S; Horn EM; Maurer MS; Kelly JW Amyloid 2015[Sep]; 22 (3): 175-80 PMID26193961show ga Placebo-controlled clinical trials are useful for identifying the dose of a drug candidate that produces a meaningful clinical response in a patient population. Currently Pfizer, Inc. is enrolling a 400-person clinical trial to test the efficacy of 20 or 80 mg of tafamidis to ameliorate transthyretin (TTR)-associated cardiomyopathy using clinical endpoints. Herein, we provide guidance for how to optimize the dose of tafamidis for each WT TTR cardiomyopathy patient using its mechanism of action as the key readout, i.e., we identify the dose of tafamidis that maximally kinetically stabilizes TTR in the blood. Tetramer dissociation is rate limiting for TTR aggregation, which appears to drive the pathology in the TTR amyloidosis. Hence we measure the TTR tetramer dissociation rate (kinetic stability) in the patients? plasma as a function of tafamidis dose to optimize the dose employed to maximize kinetic stability. Historical data tells us that a subset of patients exhibiting higher tafamidis plasma concentrations are maximally kinetically stabilized at the 20 mg tafamidis dose, whereas the patient studied herein required a 60 mg once daily dose to achieve maximum kinetic stabilization. We anticipate that establishing the dose of tafamidis that achieves maximal TTR kinetic stabilization will translate into a maximal clinical effect, but that remains to be demonstrated. äPersonalized Medicine Approach for Optimizing the Dose of Tafamidis to(epmc).pdf DeepDyve Pubget Overpricing